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Kidney ischemia/reperfusion injury (I/R) is characterized by renal dysfunction and tubular damages resulting from an early
activation of innate immunity. Recently, nicotine administration has been shown to be a powerful inhibitor of a variety of
innate immune responses, including LPS-induced toxaemia. This cholinergic anti-inflammatory pathway acts via the a7
nicotinic acetylcholine receptor (a7nAChR). Herein, we tested the potential protective effect of nicotine administration in
a mouse model of renal I/R injury induced by bilateral clamping of kidney arteries. Renal function, tubular damages and
inflammatory response were compared between control animals and mice receiving nicotine at the time of ischemia. Nicotine
pretreatment protected mice from renal dysfunction in a dose-dependent manner and through the a7nAChR, as attested by
the absence of protection in a7nAChR-deficient mice. Additionally, nicotine significantly reduced tubular damages, prevented
neutrophil infiltration and decreased productions of the CXC-chemokine KC, TNF-a and the proinflammatory high-mobility
group box 1 protein. Reduced tubular damage in nicotine pre-treated mice was associated with a decrease in tubular cell
apoptosis and proliferative response as attested by the reduction of caspase-3 and Ki67 positive cells, respectively. All
together, these data highlight that nicotine exerts a protective anti-inflammatory effect during kidney I/R through the
cholinergic a7nAChR pathway. In addition, this could provide an opportunity to overcome the effect of surgical cholinergic
denervation during kidney transplantation.
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INTRODUCTION
Ischemia/reperfusion (I/R) injury is a major cause of acute renal
failure occurring after hemorrhagic shock or major cardiovascular
surgery [1]. Despite renal replacement therapies, I/R injury remains
associated with a high morbidity and a mortality rate estimated
between 40–80% for intensive care patients. In the context of renal
transplantation, enhanced I/R injury is responsible for delayed graft
function affecting the long-term transplant outcome [2]. I/R is
associated with a large number of pathophysiological alterations
resultingeventuallyinthedestructionoftherenaltissue.I/Rinjuryis
considered as an inflammatory process originally triggered by tissue
oxygen starvation, mitochondrial dysfunction and ATP depletion
[3–6]. Upon hypoxic injury, tubular epithelial cells (TECs) acquire
a pro-inflammatory phenotype and start to release cytokines and
chemokines.Earlyafterreperfusion,amassiveinfluxofneutrophilsis
observed in the damaged areas. These neutrophils exert a crucial
role in the pathophysiology of I/R injury by the release of proteases
and oxygen-derived radicals, amplifying renal injury [7–9]. In these
conditions, TECs undergo necrosis and apoptosis. In turn, necrotic
productsactivateinnate immunity through Toll-likereceptors(TLR)
signalling pathways leading to an amplification of the inflammatory
response.
Recently, a body of evidence demonstrated that innate immune
responses can be efficiently regulated by vagus nerve, a concept
referred as the cholinergic anti-inflammatory pathway [10,11].
This regulatory pathway acts in an a7 nicotinic acetylcholine
receptor (a7nAChR)-dependent manner [12]. Acetylcholine,
which is released by stimulated vagus nerve and nicotine, an
a7nAChR agonist, suppress TNF-a production by LPS-stimulated
macrophages. The anti-inflammatory properties of the cholinergic
pathway have been also described in different in vivo models such
as LPS-induced toxaemia, Schwartzman reaction, pancreatitis and
peritonitis [13–16]. On the opposite, vagotomy or a7nAChR
deficiency dramatically enhances the sensitivity to endotoxin. One
mechanism by which the cholinergic pathway mediates its anti-
inflammatory effects is by controlling the release of high-mobility
group box 1 protein (HMGB1) [16]. A role for HMGB1 has been
recently described in the context of liver I/R [17,18]. Known as
a late mediator of endotoxic shock, HMGB1 acts simultaneously
as a chemoattractant and activator of immature dendritic cells
through TLR-2, TLR-4 and the receptor of advanced glycation
end products (RAGE) [19,20]. In the present study, we
hypothesized that nicotine pretreatment could modulate renal I/
R injury through the cholinergic anti-inflammatory pathway.
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Mice
Male C57BL/6 mice were bred in our specific pathogen-free
animal facility. Heterozygous a7nAChoR (a7+/2) B6-129S7 mice
[12] were purchased from the Jackson Laboratory (Bar Harbor,
Maine) and bred in our animal facility. First generation of a7+/+
and a72/2 animals were distinguished through genotyping
following JAX-protocol instructions. Ten to 15 weeks-old male
animals were used for I/R experiments. All mice of compared
groups were weight-matched. All animals received care in
compliance with the Principles of Laboratory Animal Care
formulated by the National Institute of Health (NIH publication
No. 86-23, revised 1985) and protocols were approved by the local
committee for animal welfare - Comite ´ d’Ethique du Biopole de
Charleroi, Universite ´ Libre de Bruxelles.
Renal ischemia/reperfusion model
Renal ischemia-reperfusion injury was induced by a 35 minutes
bilateral clamping of renal arteries as previously described [7].
Male mice were anesthetized through an intraperitoneal injection
(80 ml/10 g weight) of a mixture containing fentanyl citrate
0.08 mg/ml, fluanisone 2.5 mg/ml (VetaPharma Limited) and
midazolam 1.25 mg/ml (Roche). After a median abdominal
incision, both renal arteries were clamped during 35 minutes with
microaneuvrysm clamps. Throughout ischemic period, evidence of
clamping was confirmed by visualizing dark colour of ischemic
kidneys. After clamp removal, adequate restoration of blood flow
was checked before abdominal closure. Muscle and skin were
closed in two layers and sterile NaCl 0.9% (300 ml) was injected
subcutaneously to restore a balanced fluid volume. Mice were kept
on a warming tap (38uC) for the next 12 hours with food and
water available. Sham-operated animals underwent the same
surgical procedure without clamping and were sacrificed 1 day
after surgery. Saline-treated animals received an intraperitoneal
injection of sterile NaCl 0.9% 30 minutes before renal clamping.
One single dose of nicotine (Sigma) diluted in sterile PBS
(Phosphate-buffered saline, pH 7.2) was injected intraperitoneally
30 minutes before surgery in either sham-operated group or mice
undergoing renal I/R. I/R animals were sacrificed at day 1, 3 and
7 after reperfusion and blood and kidneys were harvested.
Plasma biochemical analysis
The recovery of renal function was determined by measuring
creatinine in plasma samples obtained after intervention by
enzyme reactions involving creatinase and using standard auto-
analyzer methods by hospital research services of Academic
Medical Center, Amsterdam [7].
Histology
Renal tissue was fixed for 24 hours in 10% formalin and embedded
inparaffin.TubulardamageswereassessedonPAS-D stained4 mm-
thick sections by scoring tubular cell necrosis, tubular dilatation, cast
deposition and brush border loss in 10 non-overlapping fields (6400
magnification) in the corticomedullary junction [7]. Injury was
scored by a pathologist blinded for the groups on a 5-point scale:
0=no damage, 1=10% of the corticomedullary junction injured,
2=10–25%, 3=25–50%, 4=50–75%, 5=more than 75%.
Preparation of renal tissue for cytokine
measurements
Kidneys were homogenised in a buffer containing 4mM EDTA,
1% Triton-X, 1% Protease Inhibitor Cocktail (Sigma) with the
MagNa Lyser (Roche). TNF-a and KC were measured using
specific ELISA (R&D Systems) according to manufacturer’s
instruction. The detection limits were 31 pg/ml and 15 pg/ml
for TNF-a and KC, respectively. Values were corrected for the
amount of protein in kidney tissue using the Bio-Rad protein assay
(Bio-Rad).
Immunostainings for neutrophils, apoptosis and
proliferation
Four mm paraffine sections were cut, deparaffinized and
rehydrated. Endogenous peroxidase activity was first quenched
by hydrogen peroxide 0.3% in methanol. For neutrophil staining,
sections were digested with pepsine (Sigma) 0.25% in 0.1 M
hydrochloric acid and non specific binding was blocked with
Normal Goat Serum 5% in PBS (DakoCytomation). Sections were
then incubated with FITC-labelled anti-mouse Ly-6G mAb
(551459; BD Biosciences), followed by an incubation with a rabbit
anti-FITC antibody (DakoCytomation) and finally with Power-
Vision HRP-conjugated goat anti-Rabbit IgG solution (Immuno-
Vision Technologies, Co). Coloration was revealed using 1% DAB
(Sigma-Aldrich) with 1% hydrogen peroxide in 0.05 M TRIS-
HCl. For macrophage, apoptose and proliferation stainings
procedures were essentially the same except that slides were
cooked in 0.1 M citrate buffer. For macrophage staining, slides
were incubated with rat anti-mouse F4/80 IgG2b mAb
(MCA497R; Serotec), rabbit anti-rat biotin (DakoCytomation)
and finally with streptavidin-ABC solution (DakoCytomation). For
apoptose, sections were incubated overnight (4uC) with Cleaved
Caspase-3 Antibody (Asp175; Cell Signaling) and for proliferation,
sections were incubated overnight (4uC) with Rabbit Monoclonal
anti-Ki67 (RM-9106; Lab Vision). Then, all sections were
incubated with Power Vision Poly-HRP-Anti-Rabbit (Immunolo-
gics) and were developed using DAB plus hydrogen peroxide in
0.05 M TRIS-HCl as described before.
Positive cells were counted on 10 non-overlapping fields in the
corticomedullary junction (6400 magnification) [7].
HMGB1 detection by western blot
Western blots were performed on cytoplasmic extracts from renal
cells. Kidneys were homogenized at 4uC in a lysis buffer
containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.1%
Igepal (INC Biochemics) mixed with 1% Protease Inhibitor
Cocktail (Sigma). After 30 minutes of incubation at 4uC and
5 min of centrifugation at 7500 rpm (4uC), supernatants contain-
ing cytoplasmic proteins were separated from the pellet and stored
at 220uC. Cytoplasmic extracts (100 mg protein/extract measured
by Bio-Rad protein assay) were separated by electrophoresis on
SDS-Polyacrylamide gel and transferred on PVDF membranes
(Hybond-P). After blocking with 5% non fat dry milk in TRIS-
buffered saline containing 0.1% Tween (TBS-T), membranes were
first incubated with Rabbit polyclonal Anti-HMGB-1 (ab11972;
Abcam) and with HRP-conjugated Anti-rabbit IgG (NA934VS;
Amersham Biosciences). Immunoreactive bands were revealed
with ECL Advance Western Blotting Detection Kit (Amersham
Biosciences) and visualised with ChemiDoc
TM XRS System (Bio-
Rad). Bands were quantified with Quantity OneH software.
Statistical analysis
Data are expressed as means+/2SEM. Non parametric
Mann-Whitney two-tailed test was used to compare experimental
groups and a p value ,0.05 was considered as statistically
significant.
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Effect of nicotine administration on ischemia/
reperfusion injury and renal dysfunction
We tested the effect of nicotine administration on renal I/R injury
in wild-type male C57BL/6 mice. A dose range from 0.1 to
1.0 mg/kg body weight was injected intraperitoneally 30 minutes
before ischemia. Nicotine administration at doses varying from
0.1 mg/kg to 1 mg/kg did not affect renal function in sham-
operated group (figure 1). As expected, saline-treated animals
rapidly worsened renal function after I/R, as attested by increased
serum levels of creatinine. Nicotine pretreatment protects renal
function in a dose-dependent manner as shown by serum
creatinine levels after different doses varying from 1 mg/kg to
0.1 mg/kg (figure 1A). The protective effect of nicotine pre-
treatment at the dose of 1 mg/kg was no longer present 3 days
after reperfusion but still observed with a dose of 0.5 mg/kg
(figure 1B). Seven days after reperfusion, serum creatinine in
control and nicotine pre-treated groups was comparable to
baseline creatinine levels measured in sham animals (data not
shown). Therefore, the dose of 0.5 mg/kg was used for the next
experiments. Kidney histology from I/R saline-treated mice
revealed significant degrees of cell necrosis, tubular dilatation,
loss of brush border and cast deposition at the corticomedullary
junction (figure 2), achieving a score of approximately 4 on a scale
of 5, 1 day and 3 days after reperfusion. Nicotine administration
significantly reduced these tubular damages 1 day and 3 days after
reperfusion. Seven days after reperfusion, both groups displayed
comparable residual levels of damages (figure 2).
Nicotine reduces the production of inflammatory
mediators after renal ischemia/reperfusion
Nicotine has been identified as a potent posttranscriptional
suppressor of pro-inflammatory cytokine production in sepsis
[12,16]. For this reason, we compared TNF-a, KC and HMGB1
levels in kidney homogenates from either nicotine-treated animals
or saline-treated controls, 24 hours after reperfusion. Nicotine
pretreatment almost completely suppressed TNF-a production
observed in saline-treated animals and significantly decreased KC
levels (Figure 3A and B). HMGB1 was measured by western blot.
We first observed an increase in renal HMGB1 after I/R
compared to sham animals. Nicotine administration significantly
decreased HMGB-1 release compared to saline-treated animals
(figure 3C and D).
Nicotine regulates neutrophil infiltrate after renal
ischemia/reperfusion
To explore whether nicotine-mediated suppression of chemokine
and cytokine production affects neutrophil influx, we performed
immunostaining using the neutrophil-specific Ly-6G mAb. As
expected, one day after reperfusion, a massive neutrophil
infiltration was observed at the corticomedullary junction in
Figure 1. Nicotine protects renal function after I/R in a dose-dependent manner. A dose range from 0.1 to 1 mg/kg body weight of nicotine has
been administrated intraperitoneally 30 minutes before the induction of renal ischemia (A). Only 0.5 mg/kg (n=12) and 1 mg/kg (n=15) of nicotine
protects renal function 1 day after renal I/R. Doses lower than 0.5 mg/kg such as 0.25 mg/kg (n=6) and 0.1 mg/kg (n=7) were not protective. Data
are expressed as mean 6 SEM, (*) p#0.05. On panel B, serum creatinine levels were measured in sham-operated animals that received either saline
solution (black bars, n=8) or nicotine at the dose of either 0.5 mg/kg body weight (white bars, n=6) or 1 mg/kg body weight (n=6) and compared
with saline-treated (black bars, n=19 at day 1 and n=15 at day 3) or nicotine treated animals at doses of 0.5 mg/kg (n=12 at day 1 and n=15 at day
3) or 1 mg/kg (n=16 at day 1 and n=12 at day 3) that underwent renal I/R. Blood samples were harvested 1 and 3 days after reperfusion. Results are
representative of three independent experiments. Data are expressed as mean 6 SEM, (*) p#0.05.
doi:10.1371/journal.pone.0000469.g001
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pretreatment (figure 4).
Nicotine administration decreases tubular epithelial
cell apoptosis and proliferation after renal ischemia/
reperfusion
Caspase activation and renal cell apoptosis are responsible for KC
chemokine production promoting neutrophil infiltration in the
kidney [21]. Because nicotine pretreatment modulates cytokine
and chemokine release and reduces neutrophil infiltration, we
measured its impact on TEC apoptosis and subsequent pro-
liferation. The cleaved caspase-3 immunostaining showed a signif-
icant decrease of apoptotic TECs in the renal corticomedullary
junction of nicotine pretreated animals compared to saline-treated
animals 24 hours after reperfusion (Figure 5). Ki67 immunostain-
ing, a nuclear protein expressed during G1-, S-, M- and G-2
phases of the cell cycle, was performed 3 days after reperfusion to
evaluate TEC proliferation. In line with the relative preservation
of the renal parenchyma in mice pretreated with nicotine, less
TECs proliferation was observed after 3 days in this group
compared to saline-treated group (Figure 5).
Nicotine-mediated protection against ischemia/
reperfusion injury is a7nAChoR-dependent
As attested by endotoxaemia experiments in genetically deficient
mice, the a7 nicotinic receptor is a pivotal element in both
naturally occurring and nicotine-mediated cholinergic anti-in-
flammatory pathway [12,16]. Therefore, we wondered if nicotine-
mediated protection against renal I/R was also a7nAChoR-
dependent. Because a7nACho-subunit deficient (a7nAChoR2/2)
mice are in another background, we first determined the
protective dose of nicotine in control littermates (0.25 mg/kg
body weight, data not shown). Then, we performed comparative
renal I/R experiments in either control littermates (referred as +/
+)o ra7nAChoR2/2 mice with and without nicotine pre-
treatment. Although nicotine pretreatment protected control
littermates from renal I/R injury, this treatment was totally
inefficient in a7nAChoR2/2 animals (Figure 6).
Figure 2. Nicotine controls tubular damage after renal I/R. Tubular damage score (A) is shown in sham-operated animals (n=7 in each group), 1
and 3 days after I/R in either saline-treated (black bars, n=17 and n=14 at day 1 and 3, respectively) or nicotine-treated animals (white bars, n=15
and n=13 at day 1 and 3, respectively). Histology of the corticomedullary junction 1 day after reperfusion from a sham-operated mouse (B, referred
as sham), a saline-treated mouse that underwent I/R (C, referred as IRI-CTRL) and a nicotine-treated mouse (D, referred as IRI-nicotine), PAS staining,
original magnification640. The PAS positive brush border (BB) is shown in panel B. Tubular casts (TC) and tubular dilatations (TD) are visible in panel
C. Similar results were obtained in two separate experiments. Data are expressed as mean 6 SEM, (*) p#0.05.
doi:10.1371/journal.pone.0000469.g002
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Our data provide evidence that nicotine, an anti-inflammatory
cholinergic agonist, protects renal function and controls tubular
damages after I/R. In the I/R model as in other settings, nicotine
most probably acts as a powerful anti-inflammatory drug by
targeting multiple factors. Neutrophil infiltration was massively
suppressed by nicotine pretreatment as attested by the Ly-6G
immunostaining. This can be, in part, explained by the important
reduction of KC chemokine release we observed and by other
non-mutually exclusive mechanisms that were not investigated
here. Indeed, Tracey et al. showed that nicotine down-regulates
adhesion molecule expression such as V-CAM, I-CAM and E-
selectin on endothelial cells through an a7nAChoR-dependent
mechanism [15]. Moreover, nicotine decreases CD44 expression
on endothelial cells [22], a molecule which is also involved in
neutrophil recruitment as shown by mouse renal I/R experiments
in which anti-CD44 treatment prevents neutrophil infiltration and
I/R injury [8]. In contrast, we observed that nicotine does not
interfere with renal macrophage infiltration (data not shown). It
has been shown that nicotine-treated macrophages lose the ability
to release proinflammatory cytokines, yet keep their capacity to
produce IL-10 [23], therefore nicotine-treated residual macro-
phages could play a role in the post-reperfusion healing process.
This hypothetical point remains to be investigated. In a compara-
ble way to what was described for nicotine in the LPS-induced
toxaemia, we also observed a down- regulation of renal levels of
TNF-a after I/R. In parallel, HMGB1, another powerful
proinflammatory factor, is up-regulated after renal I/R and down
regulated by nicotine pretreatment as described in other
experimental models [23,24]. HMGB-1 has been recently
identified as a potent pro-inflammatory mediator in sepsis and
hepatic I/R injury [16,17,25]. During severe inflammation,
HMGB-1 is translocated from the nucleus into the cytoplasm
and released actively by macrophages or passively by necrotic cells
[23,24]. In a mouse model of sepsis, Tracey et al. showed that
nicotine improves survival through the decrease of HMGB-1
released by activated macrophages still in an a7nAChR-dependent
manner [16]. During hepatic I/R, a high HMGB-1 level promotes
hepatic injury by NF-kB activation through TLR-4 binding. It has
been suggested that HMGB-1 acts as an ‘alarmin’ and amplifies
Figure 3. Nicotine down regulates TNF-a, KC and HMGB1 after renal I/R. The intra-renal production of TNF-a (A), KC (B) and HMGB1 (C and D) was
measured in sham-operated animals (n=6) and after I/R of either saline-treated animals (black bars, n=8) or nicotine-treated animals (white bars,
n=8). TNF-a and KC levels were measured by ELISA in kidney homogenates harvested 24 hours after reperfusion. All samples were corrected for total
protein amounts measured by Bio-Rad protein assay. HMGB1 specific blots (C) were performed on cytoplasmic renal extracts. From left to the right:
saline treated sham-operated animals, nicotine-treated sham-operated animals, nicotine treated I/R animals and saline treated I/R animals. Blots are
representative of 6 to 8 individual mice in each group. Quantification was assessed by the densitometry index (D). Similar results were observed in
two separate experiments. Data are expressed as mean6 SEM and (*) p#0.05.
doi:10.1371/journal.pone.0000469.g003
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PLoS ONE | www.plosone.org 5 May 2007 | Issue 5 | e469Figure 4. Nicotine pretreatment prevents neutrophil infiltration. LY-6G immunostaining was performed to assess neutrophil infiltration in the
corticomedullary junction 24 hours after I/R (panel A, magnification640). Sham operated animals displayed no neutrophil (data not shown). Nicotine
administration completely prevented neutrophil infiltration (panel B, magnification 640). Quantification is represented in panel C. Black bars
represent saline-treated animals and white bars nicotine-treated groups after either sham operation (n=6 in each group) or I/R (n=8 in each group).
Data are expressed as mean 6 SEM, (*) p#0.05.
doi:10.1371/journal.pone.0000469.g004
Figure 5. Nicotine reduces tubular epithelial cell apoptosis and subsequent proliferation. Immunostaining of cleaved caspase-3 (A, B) and Ki67 (D,
E) were performed one day and 3 days after I/R, respectively. Panel A represents TEC apoptosis in saline-treated animals (magnification 640) and
panel B represents TEC apoptosis in nicotine pre-treated animals (magnification 640). Graph C compares the quantification of apoptotic TECs in
saline-treated (black bars) or nicotine-treated animals (white bars), either after sham operation (n=6 in each group) or renal I/R (n=7 in saline-treated
group and n=10 in nicotine pretreated group). Panels D and E compare Ki-67+ cells between saline-treated animals and nicotine-treated animals
(magnification640). Graph F compares the quantification of proliferation 3 days after reperfusion (n=5 in each group). Data are expressed as mean
6 SEM, (*) p#0.05.
doi:10.1371/journal.pone.0000469.g005
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receptors [19]. This leads to the maturation of dendritic cells
which might be deleterious in transplantation because of the
sensitization of transplant recipient T cells. Consistent with these
observations, Leemans et al. observed that TLR-2 expressed on
TECs is critically involved in renal I/R injury by promoting
cytokine release, neutrophil infiltration and apoptosis [7]. The role
played by TLR4 in this setting is still unknown.
TEC apoptosis is recurrent in renal I/R injury, and is
considered as a proinflammatory event per se [21]. In our study,
TEC apoptosis was clearly diminished by nicotine pretreatment as
well as the subsequent TEC proliferation. There are at least two
reasons for this observation. First, this might result from a lesser
inflammatory environment by nicotine-mediated suppression of both
TNF-a and neutrophil infiltration. Second, nicotine has been
described to have anti-apoptotic properties [26–28]. In turn,
a reduced number of apoptotic TECs could jam the inflammatory
cascade. Indeed, apoptotic cells have been shown to enable HMGB-1
release by activated macrophages in a sepsis model [25]. Therefore,
the HMGB-1 down regulation we observed in nicotine-treated
animals could also be explained by a reduction of TEC apoptosis.
Chronic administration of nicotine has been described to be
nephrotoxic in the rat [29]. Indeed, nicotine accumulates
preferentially in the kidney, where it creates an imbalance
between the release of lipid peroxidation products and the
endogenous anti-oxidant activity [29]. We also observed that oral
administration of nicotine, started 4 days before the induction of
renal ischemia up to the sacrifice, following the protocol of van
Westerloo [14] increased renal dysfunction in our I/R model (data
not shown). In contrast, administration of 0.5 mg/kg in one-shot,
30 minutes before renal ischemia, a dose similar to that used by
others in sepsis [16], was protective. Of note, the dose of 1 mg/kg
in one-shot did not afford protection 3 days after I/R, suggesting
a late toxic effect after reperfusion. Despite a narrow range
between therapeutic and toxic doses, the clinical use of nicotine is
considered as relatively safe [30]. In this context, we also tested
another nAChoR agonist, the 1,1-dimethyl-4-phenyl-L-pioperazi-
nium-iodide (DMPP). In a liver I/R model, DMPP has been
shown to significantly decrease plasma-ALT and cytokines 3 hours
after reperfusion I/R but was ineffective 24 h of reperfusion [31].
In our model, DMPP also protected from renal I/R injury but
virtually no advantage was observed compared with nicotine (data
not shown).
The absence of a7nAChoR abolished the protective effect of
nicotine pretreatment. This observation is in line with others
showing that the integrity of the cholinergic anti-inflammatory
pathway requires the a7nAChoR expression. Whether nicotine-
mediated protection results from a direct interaction with tubular
epithelial cells or from an indirect effect on innate immune
response or both, remains to be determined. This suggests that
a7nAChoR-specific agonists could be useful for preventing acute
renal failure in several clinical settings.
In summary, our data demonstrate that nicotine administration
protects renal function and limits tubular damage after I/R
through an a7nAChR-dependent regulation of innate immune
response. This suggests that nicotinic agonists should be
considered for the prevention of acute renal failure occurring in
major cardiovascular surgery and renal transplantation.
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